Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2017

01-06-2017 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma

Authors: Caitlin A. Hester, Ali A. Mokdad, Adam C. Yopp

Published in: Current Hepatology Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

The purposes of the current review are to (1) define multidisciplinary care and a proposed composition for a multidisciplinary team and (2) summarize process and outcome measures associated with multidisciplinary care for patients with hepatocellular carcinoma (HCC).

Recent Findings

There has been a shift from multidisciplinary tumor boards to multidisciplinary clinics, which facilitates greater provider discussion and interaction over patients’ treatment course. Although most studies examining the effect of multidisciplinary care for the management of a newly diagnosed patient with HCC rely on surrogate measures of quality cancer care, recent studies have demonstrated significant improvement of stage-stratified survival.

Summary

HCC is a complex and heterogeneous disease due to the concomitant presence of underlying liver disease and cancer. Given the variety of available treatment options and data showing improved outcomes, it should be considered best practice for HCC patients to be managed by a multidisciplinary team.
Literature
1.
Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA oncology. 2015;1(4):505–27.CrossRef
2.
Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37.CrossRefPubMedPubMedCentral
3.
Wright FC, De Vito C, Langer B, Hunter A. Expert panel on multidisciplinary cancer conference S. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer. 2007;43(6):1002–10.CrossRefPubMed
4.
Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr. 2010;2010(40):72–80.CrossRefPubMedPubMedCentral
5.
Warnecke R, Fennell M, Havlicek P. Network demonstration projects and cancer control: the head and neck demonstration networks. Prog Clin Biol Res. 1983;120:247–65.PubMed
6.
Kane R. Organizing to improve the management of a disease: an overview of the breast-cancer networks. Prog Clin Biol Res. 1983;120:211–30.PubMed
7.
Clauser SB, Johnson MR, O’Brien DM, Beveridge JM, Fennell ML, Kaluzny AD. Improving clinical research and cancer care delivery in community settings: evaluating the NCI community cancer centers program. Implementation science : IS. 2009;4:63.CrossRefPubMedPubMedCentral
8.
King M, Jones L, McCarthy O, Rogers M, Richardson A, Williams R, et al. Development and pilot evaluation of a complex intervention to improve experienced continuity of care in patients with cancer. Br J Cancer. 2009;100(2):274–80.CrossRefPubMed
9.
Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003;12(1):4–13.
10.
• Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57(5):1858–68. This important manuscript outlines the most important factors associated with the receipt of care in a VA population outlying the heterogeneity of care and the complex nature of providing good cancer care. CrossRefPubMedPubMedCentral
11.
Chirikov VV, Mullins CD, Hanna N, Breunig IM, Seal B, Shaya FT. Multispecialist care and mortality in hepatocellular carcinoma. Am J Clin Oncol. 2015;38(6):557–63.CrossRefPubMed
12.
Lemieux-Charles L, McGuire WL. What do we know about health care team effectiveness? A review of the literature. Medical care research and review : MCRR. 2006;63(3):263–300.CrossRefPubMed
13.
Alexander JA, Lichtenstein R, Jinnett K, Wells R, Zazzali J, Liu D. Cross-functional team processes and patient functional improvement. Health Serv Res. 2005;40(5 Pt 1):1335–55.CrossRefPubMedPubMedCentral
14.
Shortell SM, Marsteller JA, Lin M, Pearson ML, Wu SY, Mendel P, et al. The role of perceived team effectiveness in improving chronic illness care. Med Care. 2004;42(11):1040–8.CrossRefPubMed
15.
• Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: a model for therapy. J Multidiscip Healthc. 2013;6:189–95. An excellent overview on the multitude of treatment strategies utilized in a newly diagnosed patient with HCC and how these treatments are best decided in a multidisciplinary format. CrossRefPubMedPubMedCentral
16.
• Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21(4):1287–95. This manuscript details a stage stratified benefit in overall survival upon the establishment of a multidiscliplinary HCC clinic. CrossRefPubMed
17.
Mokdad A, Browning T, Mansour JC, Zhu H, Singal AG, Yopp AC. Implementation of a voice messaging system is associated with improved time-to-treatment and overall survival in patients with hepatocellular carcinoma. J Natl Compr Cancer Netw. 2016;14(1):38–46.CrossRef
18.
Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilization and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38(7):703–12.CrossRefPubMedPubMedCentral
19.
Singal AG, Waljee AK, Patel N, Chen EY, Tiro JA, Marrero JA, Yopp AC. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netwk. 2013;11(9):1101–8.CrossRef
20.
Gashin L, Tapper E, Babalola A, Lai KC, Miksad R, Malik R, et al. Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2014;16(11):1009–15.CrossRef
21.
Zhang J, Mavros MN, Cosgrove D, Hirose K, Herman JM, Smallwood-Massey S, et al. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol. 2013;20(2):e123–31.CrossRefPubMedPubMedCentral
22.
Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a veterans affairs medical Center improves survival. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2008;10(6):405–11.CrossRef
Metadata
Title
Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma
Authors
Caitlin A. Hester
Ali A. Mokdad
Adam C. Yopp
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0342-1

Other articles of this Issue 2/2017

Current Hepatology Reports 2/2017 Go to the issue

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?

Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)

Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?

Hepatitis B (J Lim, Section Editor)

Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)

Portal Vein Thrombosis and Cirrhosis: The Role of Anticoagulation

Hepatitis B (J Lim, Section Editor)

Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits